Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Single-Blind Trial of Risperidone vs. Paroxetine for Treatment of Panic Attacks

This study has been completed.
Information provided by:
Beth Israel Medical Center Identifier:
First received: April 3, 2007
Last updated: November 30, 2010
Last verified: November 2010
This study compares the efficacy of risperidone to that of paroxetine in the treatment of panic attacks in patients with Panic Disorder and with Major Depressive Disorder with Panic attacks and compares the side effect profile of risperidone vs. paroxetine in treatment of panic attacks and compares response rates of risperidone vs. paroxetine in treatment of panic attacks.

Condition Intervention
Major Depression With Panic Attacks
Panic Disorder
Drug: Paroxetine
Drug: Risperidone

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
Official Title: A Single-Blind Trial of Risperidone vs. Paroxetine for Treatment of Panic Attacks

Resource links provided by NLM:

Further study details as provided by Beth Israel Medical Center:

Primary Outcome Measures:
  • Hamilton Anxiety Rating Scale

Secondary Outcome Measures:
  • Hamilton Depression Rating Scale
  • Panic Disorder Severity Scale
  • Sheehan Panic and Anxiety Scale - Patient rated
  • Clinical Global Impressions Scale

Estimated Enrollment: 90
Study Start Date: June 2002
Study Completion Date: June 2003
Primary Completion Date: June 2003 (Final data collection date for primary outcome measure)
  Show Detailed Description


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Males and females, ages 18-55.
  • Ability to sign an informed consent
  • Diagnosis of Panic Disorder, or MDD with Panic attacks, single episode, recurrent, or chronic
  • HAM-A score >17

Exclusion Criteria:

  • Alcohol or substance abuse within the last 6 months
  • Current diagnosis of Obsessive-Compulsive Disorder
  • Current diagnosis of Schizophrenia, Schizoaffective Disorder, or Bipolar Mood Disorder
  • Use of antipsychotic medications over the two months preceding enrollment in the study
  • Changes in antidepressant or mood stabilizer dosing over the two months preceding enrollment in the study
  • Previous adverse reaction to risperidone or paroxetine.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00457106

United States, New York
Beth Israel Medical Center
New York, New York, United States, 10003
Sponsors and Collaborators
Beth Israel Medical Center
Principal Investigator: Igor I Galynker, M.D., Ph.D. Beth Israel Medical Center
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Igor Galynker, Beth Israel medical Center Identifier: NCT00457106     History of Changes
Other Study ID Numbers: IRB#: 082-02
Study First Received: April 3, 2007
Last Updated: November 30, 2010

Keywords provided by Beth Israel Medical Center:

Additional relevant MeSH terms:
Depressive Disorder, Major
Panic Disorder
Depressive Disorder
Mood Disorders
Mental Disorders
Anxiety Disorders
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Serotonin Antagonists
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Dopamine Antagonists
Dopamine Agents processed this record on April 28, 2017